Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial registered on ANZCTR
Registration number
ACTRN12611000123943
Ethics application status
Approved
Date submitted
2/02/2011
Date registered
3/02/2011
Date last updated
26/02/2013
Type of registration
Prospectively registered
Titles & IDs
Public title
A randomized, placebo controlled, double blind, phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single escalating doses of SAN-300 when administered to healthy subjects and patients with rheumatoid arthritis
Query!
Scientific title
A phase 1 study of healthy subjects and patients with rheumatoid arthritis receiving single doses of SAN-300 or placebo to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SAN-300
Query!
Secondary ID [1]
253526
0
Santarus, Inc. Study C2011-0301
Query!
Universal Trial Number (UTN)
Nil
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Active Rheumatoid Arthritis
261085
0
Query!
Condition category
Condition code
Inflammatory and Immune System
259226
259226
0
0
Query!
Rheumatoid arthritis
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
SAN-300 is a humanized anti-VLA-1 MAb. Eight cohorts of healthy subjects, plus 1 cohort of patients with rheumatoid arthritis, will receive single doses ranging from 0.03 mg/kg to 2 mg/kg, intravenously infused over 4 hours. Additionally, 3 Cohorts of healthy subjects will receive a single dose of SAN-300 by subcutaneous injection (an injection just beneath the skin). (The dose of SAN-300 in each Cohort is listed below: Cohort A (healthy subjects): 0.03 mg/kg Cohort B (healthy subjects): 0.1 mg/kg Cohort C (healthy subjects): 0.3 mg/kg Cohort D (healthy subjects): 1.0 mg/kg Cohort E (healthy subjects): 0.6 mg/kg Cohort F (healthy subjects): 0.8 mg/kg Cohort G (healthy subjects): 1.0 mg/kg Cohort H (healthy subjects): 2.0 mg/kg Cohort I (Rheumatoid Arthritis patients) 2.0 mg/kg. The subcutaneous cohorts are; Cohort J (healthy subjects): 2 mg/kg Cohort K (healthy subjects): 4 mg/kg Cohort L (healthy subjects): 6 mg/kg
Query!
Intervention code [1]
257955
0
Treatment: Drugs
Query!
Comparator / control treatment
Placebo for IV infusion is normal saline.
Placebo for subcutaneous (SC) injection is a histidine solution (pH 6) with a small amount of riboflavin for coloring so that it matches the drug product.
Query!
Control group
Placebo
Query!
Outcomes
Primary outcome [1]
262059
0
The safety and tolerability after a single dose of SAN-300 through 1 month after dosing.
Safety and tolerability will be assessed by serum chemistry, hematology, urinalysis, physical exam, vital signs, and electrocardiogram.
Query!
Assessment method [1]
262059
0
Query!
Timepoint [1]
262059
0
Subjects will receive the dose of study drug and remain in the clinic for 24 hours. There are 5 follow up visits conducted over 1 month (Day 3, Day 8, Day 15, Day 22 and Day 29).
Query!
Secondary outcome [1]
273069
0
Characterization of the pharmacokinetics and pharmacodynamics after a single dose of SAN-300, through 1 month after dosing
Query!
Assessment method [1]
273069
0
Query!
Timepoint [1]
273069
0
Subjects will receive the dose of study drug and remain in the clinic for 24 hours. There are 5 follow up visits conducted over 1 month (Day 3, Day 8, Day 15, Day 22 and Day 29).
Query!
Eligibility
Key inclusion criteria
Healthy Subjects:
-Healthy Men and Women
-18 to 55 years of age
-Those who are of child-bearing potential must be willing to use adequate birth control measures during the study.
Participation in the study lasts approximately 1 month.
Rheumatoid Arthritis (RA) Patients:
-18 to 65 years of age
-Diagnosis of RA for greater than or equal to 6 months; swollen joint count greater than or equal to 5 and tender joint count greater than or equal to 5; on current background therapy.
-Those who are of child-bearing potential must be willing to use adequate birth control measures during the study.
Participation in the study lasts approximately 1 month.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
65
Years
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
Yes
Query!
Key exclusion criteria
Healthy Subjects and Patients with Rheumatoid Arthritis:
-History of malignancy, carcinoma, other major diseases or severe allergic reactions.
-History of clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal, and/or other major diseases.
-History of opportunistic infection or recurrent clinically significant infections.
-History of malaria or travel to a malaria endemic region within one year.
-History of positive blood test for hepatitis C, hepatitis B or HIV.
-History of tuberculosis or positive QuantiFERON-TB Gold test.
-History of drug or alcohol abuse.
-Any live immunization/vaccination within 4 weeks before study drug administration.
Women who are pregnant or breastfeeding will be excluded.
Rheumatoid Arthritis Patients:
-Functional Class IV as defined by ACR classification.
-History of significant systemic involvement secondary to RA.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
When it is determined that the subject is eligible for the study and meets all the inclusion and exclusion criteria, they will be assigned to be enrolled in a sequential manner into one of the dosing groups. Sealed opaque envelopes will be used to conceal the treatment assignment. Within each dosing group, subjects will be randomly assigned to receive either SAN-300 or placebo. Dosing groups A, B, C, D, E, F, G, H, J, K and L include the healthy subjects and dosing group I includes the patients with active rheumatoid arthritis.
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Within each dosing group, subjects will be randomly assigned to receive either SAN-300 or placebo using a randomisation table created by computer software. In Cohorts A, B, E, F, G, H, J, K and L four subjects will receive SAN-300 and 2 will receive placebo. In Cohorts C and I, 6 subjects will receive SAN-300 and 2 will receive placebo. In Cohort D, 3 subjects will recieve SAN-300 and 1 will receive placebo.
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Pharmacokinetics / pharmacodynamics
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Date of first participant enrolment
Anticipated
7/03/2011
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
Query!
Sample size
Target
74
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
Query!
Funding & Sponsors
Funding source category [1]
258417
0
Commercial sector/Industry
Query!
Name [1]
258417
0
Santarus, Inc.
Query!
Address [1]
258417
0
3721 Valley Centre Drive, Suite 400
San Diego, California, 92130
Query!
Country [1]
258417
0
United States of America
Query!
Funding source category [2]
286806
0
Commercial sector/Industry
Query!
Name [2]
286806
0
Santarus, Inc.
Query!
Address [2]
286806
0
3611 Valley Centre Drive, San Diego, CA 92130
Query!
Country [2]
286806
0
United States of America
Query!
Primary sponsor type
Commercial sector/Industry
Query!
Name
Santarus, Inc.
Query!
Address
3611 Valley Centre Drive, Suite 400, San Diego, California 92130
Query!
Country
United States of America
Query!
Secondary sponsor category [1]
257568
0
None
Query!
Name [1]
257568
0
Query!
Address [1]
257568
0
Query!
Country [1]
257568
0
Query!
Ethics approval
Ethics application status
Approved
Query!
Ethics committee name [1]
260395
0
The Alfred Hospital Ethics Committee
Query!
Ethics committee address [1]
260395
0
55 Commercial Road 3004, Melbourne Victoria
Query!
Ethics committee country [1]
260395
0
Australia
Query!
Date submitted for ethics approval [1]
260395
0
17/01/2011
Query!
Approval date [1]
260395
0
Query!
Ethics approval number [1]
260395
0
Query!
Ethics committee name [2]
287019
0
Bellberry Human Research Ethics Committee
Query!
Ethics committee address [2]
287019
0
229 Greenhil Rd
Dulwich, SA 5065
Query!
Ethics committee country [2]
287019
0
Query!
Date submitted for ethics approval [2]
287019
0
04/01/2012
Query!
Approval date [2]
287019
0
18/01/2012
Query!
Ethics approval number [2]
287019
0
New ethics HREC. Please modify.
Query!
Ethics committee name [3]
288872
0
There is no new Ethics committee
Query!
Ethics committee address [3]
288872
0
Query!
Ethics committee country [3]
288872
0
Query!
Date submitted for ethics approval [3]
288872
0
Query!
Approval date [3]
288872
0
Query!
Ethics approval number [3]
288872
0
Query!
Ethics committee name [4]
288873
0
There is no new Ethics committee
Query!
Ethics committee address [4]
288873
0
Query!
Ethics committee country [4]
288873
0
Query!
Date submitted for ethics approval [4]
288873
0
Query!
Approval date [4]
288873
0
Query!
Ethics approval number [4]
288873
0
Query!
Summary
Brief summary
Study C2011-0301 is the first study in man for SAN-300. SAN-300 is being developed for the treatment of rheumatoid arthritis. SAN-300 will be administered intravenously in 9 cohorts and subcutaneously in 3 cohorts. Approximately 66 healthy volunteers and approximately 8 patients with active rheumatoid arthritis will be enrolled to receive a single dose of SAN-300 or Placebo. Participation in the study is approximately 1 month, including dosing and follow-up visits. Subjects will receive the dose of study drug and remain in the clinic for 24 hours. There are 5 follow up visits conducted over 1 month.
Query!
Trial website
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
32159
0
Andrew Redfern
Query!
Address
32159
0
Linear Clinical Research, 1st Floor, B Block, Hospital Avenue, Nedlands WA 6009
Query!
Country
32159
0
Australia
Query!
Phone
32159
0
+ 61 89346 3660
Query!
Fax
32159
0
Query!
Email
32159
0
[email protected]
Query!
Contact person for public queries
Name
15406
0
Mr Cameron Johnson
Query!
Address
15406
0
Linear Clinical Research
1st Floor, B Block, Hospital Avenue
Nedlands WA 6009
Query!
Country
15406
0
Australia
Query!
Phone
15406
0
+61 (0) 8 6382 5100
Query!
Fax
15406
0
+61 (0) 8 9381 4453
Query!
Email
15406
0
[email protected]
Query!
Contact person for scientific queries
Name
6334
0
Mr Cameron Johnson
Query!
Address
6334
0
Linear Clinical Research
1st Floor, B Block, Hospital Avenue
Nedlands WA 6009
Query!
Country
6334
0
Australia
Query!
Phone
6334
0
+61 (0) 8 6382 5100
Query!
Fax
6334
0
+61 (0) 8 9381 4453
Query!
Email
6334
0
[email protected]
Query!
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Documents added manually
No documents have been uploaded by study researchers.
Documents added automatically
No additional documents have been identified.
Download to PDF